REFRACTORY PTLD WITH DLBCL PHENOTYPE TREATED WITH CD19 CAR T-CELL THERAPY

被引：0
|
作者：
Whitman, Abbie [1 ]
Damodharan, Sudarshawn [1 ]
Capitini, Christian [1 ]
机构：
[1] Univ Wisconsin, Madison, WI USA
来源：
PEDIATRIC BLOOD & CANCER | 2023年 / 70卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
160
引用
收藏
页码：S73 / S74
页数：2
相关论文
共 50 条
  • [21] Oligoclonal T-cell expansion in a patient with bone marrow failure after CD19 CAR-T therapy for Richter-transformed DLBCL
    Rejeski, Kai
    Wu, Zhijie
    Blumenberg, Viktoria
    Kunz, Wolfgang G.
    Mueller, Susanna
    Kajigaya, Sachiko
    Gao, Shouguo
    Buecklein, Veit L.
    Froelich, Lisa
    Schmidt, Christian
    von Bergwelt-Baildon, Michael
    Feng, Xingmin
    Young, Neal S.
    Subklewe, Marion
    BLOOD, 2022, 140 (20) : 2175 - 2179
  • [22] Glofitamab Treatment in Relapsed or Refractory DLBCL after CAR T-Cell Therapy
    Rentsch, Vera
    Seipel, Katja
    Banz, Yara
    Wiedemann, Gertrud
    Porret, Naomi
    Bacher, Ulrike
    Pabst, Thomas
    CANCERS, 2022, 14 (10)
  • [23] Prognostic significance of immune reconstitution following CD19 CAR T-cell therapy for relapsed/refractory B-cell lymphoma
    Stock, Sophia
    Bucklein, Veit L.
    Blumenberg, Viktoria
    Magno, Giulia
    Emhardt, Alica-Joana
    Holzem, Alessandra M. E.
    dos Santos, David M. Cordas
    Schmidt, Christian
    Griesshammer, Stefanie
    Frolich, Lisa
    Kobold, Sebastian
    von Bergwelt-Baildon, Michael
    Rejeski, Kai
    Subklewe, Marion
    HEMASPHERE, 2025, 9 (01):
  • [24] Anti-CD19 CAR T-cell therapy remission despite prior anti-CD19 antibody Tafasitamab in relapsed/refractory DLBCL
    Tabbara, Nadeem
    Gaut, Daria
    Oliai, Caspian
    Lewis, Tara
    de Vos, Sven
    LEUKEMIA RESEARCH REPORTS, 2021, 16
  • [25] CD19 CAR T-cell therapy and prophylactic anakinra in relapsed or refractory lymphoma: phase 2 trial interim results
    Jae H. Park
    Karthik Nath
    Sean M. Devlin
    Craig S. Sauter
    M. Lia Palomba
    Gunjan Shah
    Parastoo Dahi
    Richard J. Lin
    Michael Scordo
    Miguel-Angel Perales
    Roni Shouval
    Ana Alarcon Tomas
    Elizabeth Cathcart
    Elena Mead
    Bianca Santomasso
    Andrei Holodny
    Renier J. Brentjens
    Isabelle Riviere
    Michel Sadelain
    Nature Medicine, 2023, 29 : 1710 - 1717
  • [26] CD19 CAR T-cell therapy and prophylactic anakinra in relapsed or refractory lymphoma: phase 2 trial interim results
    Park, Jae H.
    Nath, Karthik
    Devlin, Sean M.
    Sauter, Craig S.
    Palomba, M. Lia
    Shah, Gunjan
    Dahi, Parastoo
    Lin, Richard J. J.
    Scordo, Michael
    Perales, Miguel-Angel
    Shouval, Roni
    Tomas, Ana Alarcon
    Cathcart, Elizabeth
    Mead, Elena
    Santomasso, Bianca
    Holodny, Andrei
    Brentjens, Renier J.
    Riviere, Isabelle
    Sadelain, Michel
    NATURE MEDICINE, 2023, 29 (07) : 1710 - +
  • [27] MYELOID CELL PHENOTYPE IN THE SETTING OF CD19-DIRECTED CAR T-CELL THERAPY
    Lust, Hannah
    Chaudhury, Sonali
    Miller, Stephen
    PEDIATRIC BLOOD & CANCER, 2022, 69
  • [28] TET2 DISRUPTION ENHANCES THE EFFICACY OF CD19 CAR T-CELL THERAPY
    不详
    CANCER DISCOVERY, 2018, 8 (07) : 793 - 793
  • [29] CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy for Systemic Autoimmune Diseases
    Cingireddy, Ananya Reddy
    Flores, Brianna
    Wuthrich, John
    Cingireddy, Anirudh Reddy
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2024, 16 (05)
  • [30] Low rate of subsequent malignant neoplasms after CD19 CAR T-cell therapy
    Hsieh, Emily M.
    Myers, Regina M.
    Yates, Bonnie
    Annesley, Colleen
    John, Samuel
    Taraseviciute, Agne
    Steinberg, Seth M.
    Sheppard, Jennifer
    Chung, Perry
    Chen, Lee
    Lee, Daniel W.
    DiNofia, Amanda
    Grupp, Stephan A.
    Verneris, Michael R.
    Laetsch, Theodore W.
    Bhojwani, Deepa
    Brown, Patrick A.
    Pulsipher, Michael A.
    Rheingold, Susan R.
    Gardner, Rebecca A.
    Gore, Lia
    Shah, Nirali N.
    Lamble, Adam J.
    BLOOD ADVANCES, 2022, 6 (17) : 5222 - 5226
12345